Clinical Trials Industry News More

1. Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial 10/27/2011
   DelMar Pharmaceuticals today announced the initiation of the Company's planned clinical trial with its lead drug candidate, VAL-083, for the treatment of refractory glioblastoma multiforme (GBM).
2. Positive Phase III Data On Bayer's Investigational Drug Alpharadin Show Significant Increase In Overall Survival 10/4/2011
   Bayer HealthCare Pharmaceuticals recently announced positive data on its investigational drug Alpharadin (radium-223 chloride) from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
3. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis 9/21/2011
   Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.
4. RXi Pharmaceuticals Provides Positive NeuVax™ Phase 3 Clinical Trial Update 9/13/2011
   RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today announced a clinical trial update on its lead program, NeuVax™ (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin®).
5. GSK And Theravance Announce Results Of Two Pivotal Phase III Studies For Relovair In COPD 6/7/2011
   GlaxoSmithKline (GSK) and Theravance, Inc. recently announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with chronic obstructive pulmonary disease (COPD).
6. NIH Stops Clinical Trial On Combination Cholesterol Treatment 5/27/2011
   The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.
7. Radius Announces Closing Of $91M Financing To Advance BA058 Injection Into Phase 3 Osteoporosis Study 5/25/2011
   Radius Health, Inc. (“Radius”) today announced that the company has raised approximately $91M in its third financing round, including $66M in equity financing and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance LLC to a $25 million multidraw term loan facility.
8. Clinical Trial Starts In Autoimmune/Inflammatory Diseases Shift From Rheumatology To Asthma And COPD Disorders 5/11/2011
   Citeline, the world’s leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the autoimmune/inflammation therapeutic area to uncover trends and patterns regarding drug development.
9. Omnicare Clinical Research Acquired By Nautic Partners, LLC 4/29/2011
   Omnicare Clinical Research (CR), a leading global, full-service contract research organization (CRO), announced recently that it has been acquired by Nautic Partners, LLC, a private equity firm based in Providence, R.I.
10. Alzheimer's Disease Neuroimaging Initiative (ADNI) In Clinical Trials 4/18/2011
    Last week was a highpoint for the ADNI group with the presentation of the Nancy and Ronald Reagan award at the national Alzheimer’s Disease Gala in Washington DC, and the face to face meeting of the ADNI researchers and private partners in LA preceding the American Academy of Neurology meeting in Hawaii. I had the privilege of attending the first two with my colleague Dr. Chahin Pachai. He then went on to Hawaii (Note to self – next time get Chahin to write a blog and I’ll go to Hawaii)!